Przeglądanie według Autor "Ramniwas, Seema"

Aktualnie wyświetlane 1 - 2 z 2

Effectiveness of novel iron regulators in the treatment of diabetic nephropathy
(Publishing Office of the University of Rzeszow, 2023-09) Banerjee, Dekai; Kaur, Ginpreet; Chatterjee, Bappaditya; Joshi, Hemant; Ramniwas, Seema; Tuli, Hardeep Singh
Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.
Exploring the versatility of ciclopirox – from anti-fungal to anticancer agent and beyond
(Publishing Office of the University of Rzeszow, 2023-12) Singh, Dhishank; Kaur, Ginpreet; Chintamaneni, Meena; Joshi, Hemant; Ramniwas, Seema; Tuli, Hardeep Singh
Introduction and aim. Ciclopirox has been treating fungal infections for decades. Recent studies suggest ciclopirox may be repurposed to treat cancer, viral infections, and neurological disorders. Ciclopirox exerts anticancer by inhibiting multiple pathways of cancer cell growth and survival and anti-viral actions by reducing viral replication and altering the host immunological response to viral infection. Recent research suggests that ciclopirox may protect against neurodegenerative illnesses including Alzheimer’s and Parkinson’s. This narrative review shows ciclopirox’s potential to treat cancer, viral infections, and neurological diseases. Material and methods. Current relevant research publications focused on ciclopirox and its repurposing medicinal potential, therefore a well-designed technique was used to find them. „Ciclopirox”, „Anti-fungal”, „Anti-cancer”, „Repurposing”, and „Therapeutic potential” were used to search PubMed, Web of Science, EMBASE, and Google Scholar. Analysis of literature. Ciclopirox may reduce oxidative stress and inflammation, which may cause several illnesses. Overall, the repurposing of ciclopirox for the treatment of cancer, viral infections, and neurodegenerative disorders represents a promising avenue of research that warrants further investigation. Conclusion. It was concluded that CPX and olamine derivatives as outstanding antifungal medications, as well as provide information on ongoing research to use them for other illnesses.